Clinical trial
GW572016, An Oral Drug For Colorectal Cancer Patients Having Prior Therapy With…
NCT00044343 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00044343 |
|---|---|
| Title | GW572016, An Oral Drug For Colorectal Cancer Patients Having Prior Therapy With 5-FU Plus CPT-11 And/Or Oxaliplatin |
| Official title | An Open-Label, Multicenter, Phase II Study of Oral Lapatinib (GW572016) as Single Agent, Second-Line Therapy in Subjects With Metastatic Colorectal Cancer Who Have Progressed on First-Line Therapy With 5-Fluorouracil in Combination With Irinotecan or Oxaliplatin |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Colorectal Cancer |
| Intervention type | Drug |
| Interventions | lapatinib |
| Enrollment | 80 |
| Start date | Sep 1, 2002 |
| Primary completion | Oct 1, 2003 |
| Completion | Oct 1, 2003 |
| First posted | Aug 28, 2002 |
| Last update posted | Jul 10, 2014 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: